Cargando…

Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders

Alveolar hypoxia is the most prominent feature of high altitude environment with well-known consequences for the cardio-pulmonary system, including development of pulmonary hypertension. Pulmonary hypertension due to an exaggerated hypoxic pulmonary vasoconstriction contributes to high altitude pulm...

Descripción completa

Detalles Bibliográficos
Autores principales: Sydykov, Akylbek, Mamazhakypov, Argen, Maripov, Abdirashit, Kosanovic, Djuro, Weissmann, Norbert, Ghofrani, Hossein Ardeschir, Sarybaev, Akpay Sh., Schermuly, Ralph Theo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916528/
https://www.ncbi.nlm.nih.gov/pubmed/33578749
http://dx.doi.org/10.3390/ijerph18041692
_version_ 1783657497665470464
author Sydykov, Akylbek
Mamazhakypov, Argen
Maripov, Abdirashit
Kosanovic, Djuro
Weissmann, Norbert
Ghofrani, Hossein Ardeschir
Sarybaev, Akpay Sh.
Schermuly, Ralph Theo
author_facet Sydykov, Akylbek
Mamazhakypov, Argen
Maripov, Abdirashit
Kosanovic, Djuro
Weissmann, Norbert
Ghofrani, Hossein Ardeschir
Sarybaev, Akpay Sh.
Schermuly, Ralph Theo
author_sort Sydykov, Akylbek
collection PubMed
description Alveolar hypoxia is the most prominent feature of high altitude environment with well-known consequences for the cardio-pulmonary system, including development of pulmonary hypertension. Pulmonary hypertension due to an exaggerated hypoxic pulmonary vasoconstriction contributes to high altitude pulmonary edema (HAPE), a life-threatening disorder, occurring at high altitudes in non-acclimatized healthy individuals. Despite a strong physiologic rationale for using vasodilators for prevention and treatment of HAPE, no systematic studies of their efficacy have been conducted to date. Calcium-channel blockers are currently recommended for drug prophylaxis in high-risk individuals with a clear history of recurrent HAPE based on the extensive clinical experience with nifedipine in HAPE prevention in susceptible individuals. Chronic exposure to hypoxia induces pulmonary vascular remodeling and development of pulmonary hypertension, which places an increased pressure load on the right ventricle leading to right heart failure. Further, pulmonary hypertension along with excessive erythrocytosis may complicate chronic mountain sickness, another high altitude maladaptation disorder. Importantly, other causes than hypoxia may potentially underlie and/or contribute to pulmonary hypertension at high altitude, such as chronic heart and lung diseases, thrombotic or embolic diseases. Extensive clinical experience with drugs in patients with pulmonary arterial hypertension suggests their potential for treatment of high altitude pulmonary hypertension. Small studies have demonstrated their efficacy in reducing pulmonary artery pressure in high altitude residents. However, no drugs have been approved to date for the therapy of chronic high altitude pulmonary hypertension. This work provides a literature review on the role of pulmonary hypertension in the pathogenesis of acute and chronic high altitude maladaptation disorders and summarizes current knowledge regarding potential treatment options.
format Online
Article
Text
id pubmed-7916528
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79165282021-03-01 Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders Sydykov, Akylbek Mamazhakypov, Argen Maripov, Abdirashit Kosanovic, Djuro Weissmann, Norbert Ghofrani, Hossein Ardeschir Sarybaev, Akpay Sh. Schermuly, Ralph Theo Int J Environ Res Public Health Review Alveolar hypoxia is the most prominent feature of high altitude environment with well-known consequences for the cardio-pulmonary system, including development of pulmonary hypertension. Pulmonary hypertension due to an exaggerated hypoxic pulmonary vasoconstriction contributes to high altitude pulmonary edema (HAPE), a life-threatening disorder, occurring at high altitudes in non-acclimatized healthy individuals. Despite a strong physiologic rationale for using vasodilators for prevention and treatment of HAPE, no systematic studies of their efficacy have been conducted to date. Calcium-channel blockers are currently recommended for drug prophylaxis in high-risk individuals with a clear history of recurrent HAPE based on the extensive clinical experience with nifedipine in HAPE prevention in susceptible individuals. Chronic exposure to hypoxia induces pulmonary vascular remodeling and development of pulmonary hypertension, which places an increased pressure load on the right ventricle leading to right heart failure. Further, pulmonary hypertension along with excessive erythrocytosis may complicate chronic mountain sickness, another high altitude maladaptation disorder. Importantly, other causes than hypoxia may potentially underlie and/or contribute to pulmonary hypertension at high altitude, such as chronic heart and lung diseases, thrombotic or embolic diseases. Extensive clinical experience with drugs in patients with pulmonary arterial hypertension suggests their potential for treatment of high altitude pulmonary hypertension. Small studies have demonstrated their efficacy in reducing pulmonary artery pressure in high altitude residents. However, no drugs have been approved to date for the therapy of chronic high altitude pulmonary hypertension. This work provides a literature review on the role of pulmonary hypertension in the pathogenesis of acute and chronic high altitude maladaptation disorders and summarizes current knowledge regarding potential treatment options. MDPI 2021-02-10 2021-02 /pmc/articles/PMC7916528/ /pubmed/33578749 http://dx.doi.org/10.3390/ijerph18041692 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sydykov, Akylbek
Mamazhakypov, Argen
Maripov, Abdirashit
Kosanovic, Djuro
Weissmann, Norbert
Ghofrani, Hossein Ardeschir
Sarybaev, Akpay Sh.
Schermuly, Ralph Theo
Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders
title Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders
title_full Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders
title_fullStr Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders
title_full_unstemmed Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders
title_short Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders
title_sort pulmonary hypertension in acute and chronic high altitude maladaptation disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916528/
https://www.ncbi.nlm.nih.gov/pubmed/33578749
http://dx.doi.org/10.3390/ijerph18041692
work_keys_str_mv AT sydykovakylbek pulmonaryhypertensioninacuteandchronichighaltitudemaladaptationdisorders
AT mamazhakypovargen pulmonaryhypertensioninacuteandchronichighaltitudemaladaptationdisorders
AT maripovabdirashit pulmonaryhypertensioninacuteandchronichighaltitudemaladaptationdisorders
AT kosanovicdjuro pulmonaryhypertensioninacuteandchronichighaltitudemaladaptationdisorders
AT weissmannnorbert pulmonaryhypertensioninacuteandchronichighaltitudemaladaptationdisorders
AT ghofranihosseinardeschir pulmonaryhypertensioninacuteandchronichighaltitudemaladaptationdisorders
AT sarybaevakpaysh pulmonaryhypertensioninacuteandchronichighaltitudemaladaptationdisorders
AT schermulyralphtheo pulmonaryhypertensioninacuteandchronichighaltitudemaladaptationdisorders